Interest Expense is the amount reported by a company or individual as an expense for borrowed money. aTyr Pharma's interest expense for the
three
months ended in Dec. 2023 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. aTyr Pharma's Operating Income for the
three
months ended in Dec. 2023 was $ -15.96 Mil. aTyr Pharma's Interest Expense for the
three
months ended in Dec. 2023 was $ 0.00 Mil.
GuruFocus does not calculate aTyr Pharma's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
aTyr Pharma Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
aTyr Pharma (NAS:LIFE) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
aTyr Pharma's Interest Expense for the
three
months ended in Dec. 2023 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Dec. 2023 was $-15.96 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2023 was $13.77 Mil.
aTyr Pharma's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
| GuruFocus does not calculate aTyr Pharma's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. aTyr Pharma Inc has enough cash to cover all of its debt. Its financial situation is stable.
aTyr Pharma (aTyr Pharma) Business Description
Traded in Other Exchanges
Address
10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Executives
| Sanjay Shukla |
officer: Chief Medical Officer |
C/O ATYR PHARMA, INC., 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO CA 92121 |
| Paul Schimmel |
director |
88 SIDNEY ST, CAMBRIDGE MA 02139 |
| Jill Marie Broadfoot |
officer: Chief Financial Officer |
3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
| Sara Zaknoen |
director |
C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121 |
| John K Clarke |
director |
C/O CARDINAL HEALTH PARTNERS, 221 NASSAU STREET, PRINCETON NJ 08542 |
| Nancy Krueger |
officer: See Remarks |
C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
| Svetlana Lucas |
director |
3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
| Jane A Gross |
director |
2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121 |
| John Mendlein |
director, officer: CEO and Executive Chairman |
|
| Ecor1 Capital Fund Qualified, L.p. |
10 percent owner |
357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
| Ashraf Amanullah |
officer: Vice President, Manufacturing |
C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
| John T Blake |
officer: Vice President, Finance |
C/O SECOND SIGHT MEDICAL PRODUCTS, INC., 12744 SAN FERNANDO ROAD, SUITE 400, SYLMAR CA 91342 |
| Timothy P Coughlin |
director |
339 NORTH GRANADOS AVE, SOLANA BEACH CA 92075 |
| Jeffrey S. Hatfield |
director |
11080 ROSELLE STREET, SAN DIEGO CA 92121 |
| David John King |
officer: See Remarks |
3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
aTyr Pharma (aTyr Pharma) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LIFE has been successfully added to your 